Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lu-OncoFAP-23

Phase 1Small molecule

PPhilogen S.p.A.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

FAPRecruiting

FAPPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

FAP

NCT06640413

Clinical

Trials by Indication[1]

FAP1 trial

A Phase I Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

Recruiting·PPhilogen S.p.A.·Phase 1·NCT06640413·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lu-OncoFAP-23. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lu-OncoFAP-23 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lu-OncoFAP-23. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Philogen S.p.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPhilogen S.p.A.

Related News